Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

478 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Microcontact printing of proteins for neuronal cell guidance.
Offenhäusser A, Böcker-Meffert S, Decker T, Helpenstein R, Gasteier P, Groll J, Möller M, Reska A, Schäfer S, Schulte P, Vogt-Eisele A. Offenhäusser A, et al. Among authors: decker t. Soft Matter. 2007 Feb 14;3(3):290-298. doi: 10.1039/b607615g. Soft Matter. 2007. PMID: 32900145 Review.
Independence of synaptic specificity from neuritic guidance.
Vogt AK, Brewer GJ, Decker T, Böcker-Meffert S, Jacobsen V, Kreiter M, Knoll W, Offenhäusser A. Vogt AK, et al. Among authors: decker t. Neuroscience. 2005;134(3):783-90. doi: 10.1016/j.neuroscience.2005.04.039. Neuroscience. 2005. PMID: 16009499
Evaluation of the inflammation-based modified Glasgow Prognostic Score (mGPS) as a prognostic and predictive biomarker in patients with metastatic colorectal cancer receiving first-line chemotherapy: a post hoc analysis of the randomized phase III XELAVIRI trial (AIO KRK0110).
Boukovala M, Modest DP, Ricard I, Fischer von Weikersthal L, Decker T, Vehling-Kaiser U, Uhlig J, Schenk M, Freiberg-Richter J, Peuser B, Denzlinger C, Peveling Genannt Reddemann C, Graeven U, Schuch G, Schwaner I, Heinrich K, Neumann J, Jung A, Held S, Stintzing S, Heinemann V, Michl M. Boukovala M, et al. Among authors: decker t. ESMO Open. 2024 May 13;9(5):103374. doi: 10.1016/j.esmoop.2024.103374. Online ahead of print. ESMO Open. 2024. PMID: 38744100
JAK-STAT signaling maintains homeostasis in T cells and macrophages.
Fortelny N, Farlik M, Fife V, Gorki AD, Lassnig C, Maurer B, Meissl K, Dolezal M, Boccuni L, Ravi Sundar Jose Geetha A, Akagha MJ, Karjalainen A, Shoebridge S, Farhat A, Mann U, Jain R, Tikoo S, Zila N, Esser-Skala W, Krausgruber T, Sitnik K, Penz T, Hladik A, Suske T, Zahalka S, Senekowitsch M, Barreca D, Halbritter F, Macho-Maschler S, Weninger W, Neubauer HA, Moriggl R, Knapp S, Sexl V, Strobl B, Decker T, Müller M, Bock C. Fortelny N, et al. Among authors: decker t. Nat Immunol. 2024 May;25(5):847-859. doi: 10.1038/s41590-024-01804-1. Epub 2024 Apr 24. Nat Immunol. 2024. PMID: 38658806 Free PMC article.
Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer: Results from the open-label, multicentre, non-interventional BRAWO study.
Lüftner D, Schuetz F, Schneeweiss A, Hartkopf A, Bloch W, Decker T, Uleer C, Stötzer O, Foerster F, Schmidt M, Mundhenke C, Tesch H, Jackisch C, Fischer T, Kreuzeder J, Guderian G, Fasching PA. Lüftner D, et al. Among authors: decker t. Int J Cancer. 2024 Jul 1;155(1):128-138. doi: 10.1002/ijc.34912. Epub 2024 Mar 6. Int J Cancer. 2024. PMID: 38447007
Final Results from RIBBIT: A Randomized Phase III Study to Evaluate Efficacy and Quality of Life in Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer Receiving Ribociclib in Combination with Endocrine Therapy or Chemotherapy with or without Bevacizumab in the First-Line Setting.
Decker T, Zaiss M, Klein D, Hahn A, Hagen V, La Rosée P, Liersch R, Wolff T, Niemeier B, Hillebrand LE, Lennartz C, Chiabudini M, Bengsch F, Indorf M, Marschner N. Decker T, et al. Breast Care (Basel). 2024 Feb;19(1):49-61. doi: 10.1159/000535135. Epub 2023 Dec 20. Breast Care (Basel). 2024. PMID: 38384487
Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer.
Fasching PA, Decker T, Hartkopf A, Nusch A, Heinrich BJ, Kurbacher C, Fuchs R, Tesch H, Krabisch P, Huober J, Kuemmel S, Brucker S, Janni W, Schneeweiss A, Schuler M, Fehm T, Lüftner D, Quiering C, Voges C, Kreuzeder J, Reinisch M. Fasching PA, et al. Among authors: decker t. Eur J Cancer. 2024 Feb;198:113480. doi: 10.1016/j.ejca.2023.113480. Epub 2023 Dec 15. Eur J Cancer. 2024. PMID: 38154393 Free article. Clinical Trial.
478 results